The Impact of Clinical Pharmacy Services on the Quality of Warfarin Anticoagulation Therapy Management
DU Li-ping1, LI Ying1, LI Ling-ling1, BAO Yun2, YOU Guo-jiao3, REN Shuang4, ZHANG Bo1, MEI Dan1*
1. Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China; 2. Department of Pharmacy, Gansu Provincial Hospital, Lanzhou 730000, China; 3. Department of Pharmacy, Air Force Medical University Xijing Hospital, Xi��an 710032, China; 4. Department of Pharmacy,Beijing Jishuitan Hospital,Beijing 100035, China
Abstract��OBJECTIVE To evaluate the effects of clinical pharmacy services in patients with warfarin and highlight the important role of clinical pharmacists. METHODS Patients in need of warfarin were enrolled as intervention group during 2016.9-2017.9 to receive standard anticoagulation management and follow-up provided by clinical pharmacists, and clinical data of patients who meet the inclusion criteria during 2013.7-2015.7 as control group was analyzed retrospectively. International normalized ratio(INR) values, maintenance doses, time to achieve therapeutic range, and etc. were recorded and TTRs (time in therapeutic range) were calculated to compare the outcomes of each group. RESULTS TTRs in intervention group were significantly higher than those in control group, and so was the percentage of patients with the best quality of warfarin therapy(47.89% vs. 20.09%,P<0.001).Time to achieve therapeutic range was shorter and the frequency of INR test was higher in intervention group compared with those in control group. Patients�� cognitive scores of warfarin therapy were substantially increased after pharmacist��s education. CONCLUSION Anticoagulation therapy management provided by clinical pharmacists could significantly improve the quality of warfarin therapy.
����Ƽ, ��Ө, ������, ��ܿ, �ȹ��, ��ˬ, �Ų�, ÷��. ҩʦ��Ԥ�Ի����ֿ�������������Ӱ��[J]. �й�ҩѧ��־, 2019, 54(9): 749-752.
DU Li-ping, LI Ying, LI Ling-ling, BAO Yun, YOU Guo-jiao, REN Shuang, ZHANG Bo, MEI Dan. The Impact of Clinical Pharmacy Services on the Quality of Warfarin Anticoagulation Therapy Management. Chinese Pharmaceutical Journal, 2019, 54(9): 749-752.
AGENO W, GALLUS A S, WITTKOWSKY A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed:American College of Chest Physicians evidence-based clinical practice guidelines. Chest,2012,141(2 suppl):44-88.
Chinese Society of Cardiology,Committee of Cardiocerebrovascular Diseases of Gerontological Society of China. China consensus of warfarin anticoagulation therapy. Chin J Intern Med(�л��ڿ���־),2013,52(1):76-82.
SPYROPOULOS A C. Managing oral anticoagulation requires expertexperience and clinical evidence. J Thromb Thrombolysis,2006,21(1):91-94.
GUPTA V,KOGUT S J,THOMPSON S. Evaluation of differences in percentage of international normalized ratios in range between pharmacist-led and physician-led anticoagulation management services. J Pharm Pract,2015,28(3):249-255.
GARWOOD C L, DUMO P, BARINGHAUS S N, et al. Quality of anticoagulation care in patients discharged from a pharmacist-managed anticoagulation clinic after stabilization of warfarin therapy. Pharmacotherapy, 2008,28(1):20-26.
LI L L, LI Y, DU L P, et al. Quality evaluation of anticoagulant therapy in patients who taking warfarin in our hospital. J China Pharm(�й�ҩ��), 2016, 27 (15):2032-2034.
ROSENDAAL F R, CANNEGIETER S C, VAN DER MEER F J, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost, 1993, 69(3):236-239.
GE W H. Handbook of Warfarin Anticoagulation Therapy for Clinical Pharmacist (�����ֿ��������ٴ�ҩʦָ���ֲ�) . Beijing: People��s Medical Publishing House, 2009: 9-64.
CAMM A J, LIP G Y, DE CATERINA R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J, 2012, 33(21):2719-2747.
CONNOLLY S J, EZEKOWITZ M D, YUSUF S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009, 361(12):1139-1151.
PATEL M R, MAHAFFEY K W, GARG J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011, 365(10):883-891.
GRANGER C B, ALEXANDER J H, MCMURRAY J J, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011, 365(11):981-992.
CONNOLLY S J, POGUE J, EIKELBOOM J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation, 2008, 118(20):2029-2037.
BAKER J W, PIERCE K L, RYALS C A. INR goal attainment and oral anticoagulation knowledge of patients enrolled in an anticoagulation clinic in a veterans affairs medical center. J Manag Care Pharm, 2011, 17(2):133-142.
JOSHUA J K, KAKKAR N. Lacunae in patient knowledge about oral anticoagulant treatment: results of a questionnaire survey. Indian J Hematol Blood Transfus, 2015, 31(2):275-280.
CHEN L,YE S W,JIANG Y H, et al. The management mode of warfarin anticoagulation clinic. Her Med (ҽҩ����), 2015, 34(2):281-283.
HU D,SUN Y. Epidemiology,risk factors for stroke,andmanagement of atrial fibrillation in China. J Am Coll Cardiol, 2008, 52:865-868.
ZHOU Z Q,HU D Y,CHEN J, et al. An epidemiological survey of atrial fibrillation in China. Chin J Intern Med(�л��ڿ���־),2004,43(7):491-494.
XI X Y, YAO D N, HUANG Y K, et al. National survey on clinical pharmacy services of tertiary hospitals in China: Part 1. Introduction of survey and basic conditions of clinical pharmacy service provision. Chin Pharm J(�й�ҩѧ��־), 2017, 52(19):1746-1752.
CUI L, XI X Y, YAO D N, et al. National survey on clinical pharmacy services of tertiary hospitals in China: Part 3. Status quo of clinical pharmacy service provision. Chin Pharm J(�й�ҩѧ��־), 2018, 53(10):837-842.